With the rise of generative AI in life sciences and healthcare, medical technology is experiencing an unprecedented efficiency revolution. From clinical research and disease diagnosis to drug development, report writing, and literature translation, AI is significantly boosting productivity and providing researchers and physicians with powerful new tools. On October 9, 2024, the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry to David Baker, Demis Hassabis, and John M. Jumper, recognizing their groundbreaking work in protein design and structure prediction. Their AlphaFold2 model solved a 50-year challenge in biology and was freely released to the global scientific community, dramatically improving protein research efficiency and enabling applications in vaccines, pharmaceuticals, and biotechnology.

To extend these breakthroughs to more research institutions, laboratories, and companies, deployment cost and complexity must be reduced. AlphaFold2 requires immense computational power and memory, as prediction complexity increases with protein sequence length. Intel has leveraged its Xeon platforms and diverse processor portfolio to provide high-performance yet cost-effective computing support for AlphaFold2. End-to-end optimizations, from preprocessing to model inference and post-processing, significantly improve efficiency while reducing memory usage. With Intel-optimized PyTorch and JIT compilation, operator fusion, and multi-instance parallelism, researchers can efficiently predict both individual proteins and complexes, making AlphaFold2 more accessible and accelerating the democratization of scientific innovation.

AI is also revolutionizing drug development. Pharmaceutical R&D traditionally faces high costs, long timelines, and high risks. AI accelerates target discovery and candidate molecule design by analyzing massive datasets. The PandaOmics platform by Yinsi Intelligent, a leading Chinese AI pharmaceutical company, integrates genetic, proteomic, and multi-omics data to rapidly identify high-relevance drug targets and biomarkers. Intel’s computing power enables efficient handling of compute-intensive tasks on cloud or local deployments, reducing R&D costs and accelerating drug discovery and innovative therapy development.

Genomic analysis represents another frontier in healthcare innovation. Previously, sequencing a human genome took years, but now it can be completed in hours. Intel collaborates with research institutions on end-to-end genomic analysis reference designs that optimize software and hardware deployment for high throughput and low power consumption. Upgrading from fourth- to fifth-generation Xeon processors, throughput increased by 61%, with a single node processing up to 14 WGS samples per day. Unit cost per sample dropped to $2.34, and power consumption to 0.341 kWh, enabling efficient, sustainable genomic research.

AI and computing also help address unequal access to medical resources. Virtual clinics allow patients in remote regions to access high-quality medical care. Leveraging computer vision, large AI models, and virtual reality, physicians can remotely guide examinations, while patients understand conditions through digital twin models, experiencing near face-to-face consultations. Intel-optimized healthcare AI models and knowledge graph technologies assist frontline doctors with diagnostics, while multi-view video consultations provide high-quality remote care, making medical resources accessible to all.

From accelerating protein structure prediction and drug discovery, to lowering genomic analysis costs, to enabling remote healthcare access, chips and computing power are driving the digital transformation of medicine. Through hardware-software co-optimization, Intel and its partners provide affordable and powerful computing foundations for researchers and doctors, removing the computational barriers to innovation and making high-quality healthcare more equitable and attainable. The convergence of AI and chip technology is opening a new era of accessible healthcare worldwide, bringing the benefits of innovation to more patients.